Friday - December 26, 2025

Category Archives: Science

Allergic Rhinitis Market Size in the US was ~USD 3,600 million in 2023 and it is further expected to increase by 2034, estimates DelveInsight

DelveInsight’s “Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Allergic Rhinitis, historical and forecasted epidemiology as well as the Allergic Rhinitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the … Continue reading →

Interstitial Lung Disease Market Size in the 7MM is projected to grow at a significant CAGR by 2032, estimates DelveInsight

DelveInsight’s “Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Interstitial Lung Disease, historical and forecasted epidemiology as well as the Interstitial Lung Disease market trends in the United States, EU4 (Germany, Spain, … Continue reading →

Axial Spondyloarthritis Market Size in the 7MM is anticipated to grow with a significant CAGR by 2034, estimates DelveInsight

DelveInsight’s “Axial Spondyloarthritis Market Insights, Epidemiology and Market Forecast–2034” report delivers an in-depth understanding of the indication axial spondyloarthritis, historical and forecasted epidemiology as well as the axial spondyloarthritis market trends in the United States, EU4 (Germany, Spain, Italy, and … Continue reading →

Asthma Clinical Trial Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Asthma Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in the Asthma pipeline landscape. It covers the Asthma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Asthma therapeutics … Continue reading →

Hepatitis B Virus Infection Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Hepatitis B Virus Infection Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Hepatitis B Virus (HBV) Infection pipeline landscape. It covers the Hepatitis B Virus Infection pipeline drug profiles, including clinical and … Continue reading →

Hiteck’s rhNGF Eye Drops (HT006.2.2) Demonstrate Favorable Safety in First-in-Human Study Published in EJPS

The study demonstrated favorable safety and tolerability across all dose groups in healthy volunteers, supporting the continued advancement of the drug’s clinical development for patients with neurotrophic keratitis (NK). Wuhan Hiteck Biopharmaceutical Co., Ltd. announced that results from the first-in-human … Continue reading →

Hypercholesterolemia Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Hypercholesterolemia Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Hypercholesterolemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product … Continue reading →

Chronic Periodontitis Clinical Trial Pipeline Gains Momentum: 10+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Chronic Periodontitis Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Periodontitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment … Continue reading →